- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00187551
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance
Partial Treatment Interruptions in HIV-1 Patients With Multi-Drug Resistant Virus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Some patients do not achieve an undetectable HIV viral load with an enfuvirtide (T20, Fuzeon) based antiretroviral regimen. As a consequence, enfuvirtide resistant virus can emerge. It is not yet known if enfuvirtide has continued virologic or immunologic benefit after the drug-resistant variant emerges. Interrupting enfuvirtide may reduce the accumulation of enfuvirtide mutations and may allow for a potent response of enfuvirtide with future regimens.
Subjects must have evidence of viral replication (HIV RNA > 1,000 copies/ml on two consecutive measurements) while on a stable antiretroviral regimen containing enfuvirtide. Patients will then interrupt enfuvirtide while continuing all other antiretroviral agents. Subjects will be seen weekly for four weeks, every two weeks for an additional 8 weeks, and then every four weeks through week 48.
Plasma HIV RNA levels and CD4+/CD8+ T cell counts will be measured in real time at each visit, and provided to the referring primary care physician. Subjects will be allowed to resume enfuvirtide at any time during the course of this study. Subjects will be encouraged to resume enfuvirtide (with or without modifying the background regimen) if plasma HIV RNA levels increase by > 0.5 log on two consecutive occasions. Subjects are seen every four weeks for 24 weeks after enfuvirtide is resumed.
Plasma will be collected at those visits for HIV RNA and stored for retrospective genotype/phenotype evaluation.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- San Francisco General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Currently receiving continuous enfuvirtide-based antiretroviral therapy.
- Documentation of recent plasma HIV RNA level greater than the lower limit of detection (measured within the preceding 4 weeks)
- Screening plasma HIV-1 RNA level > 1000 copies/mL.
- Negative serum pregnancy test (for women of childbearing potential) documented within the 14-day period prior to study entry.
- Subjects must be able to give written informed consent and agree to abide by the requirements of the study.
Exclusion Criteria:
- Unstable HIV disease status such that interrupting any antiretroviral therapy poses significant short-term risk for disease progression (as determined by study investigators and referring primary care provider).
- Female subjects who are pregnant, breastfeeding, or who plan to become pregnant during the study.
- Active hepatitis C infection requiring treatment with an interferon-based regimen.
- Evidence of active, untreated opportunistic infections or unexplained temperature which is > 38.5°C for seven consecutive days, within 30 days prior to the first screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: interruption of enfuvirtide
enfuvirtide interruption
|
treatment interruption
enfuvitide will be interrupted in patients harboring resistant virus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CD4
Time Frame: week 24
|
week 24
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Steven G Deeks, M.D., University of California, San Francisco
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Fusion Inhibitors
- Viral Fusion Protein Inhibitors
- Enfuvirtide
Other Study ID Numbers
- H8211-18804-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Interruption of enfuvirtide
-
UConn HealthColgate PalmoliveCompleted
-
Tel-Aviv Sourasky Medical CenterUnknownHIV Infections
-
Institute of Tropical Medicine, BelgiumUniversity Hospital, Ghent; Universitair Ziekenhuis Brussel; Agentschap voor... and other collaboratorsCompleted
-
University Hospital, GenevaCompletedHIV Infection | AIDSSwitzerland
-
Berkovich, Regina MD, PhD Inc.Biogen; Cedars-Sinai Medical CenterRecruitingMultiple Sclerosis | Multiple Sclerosis, Relapsing-RemittingUnited States
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaboratorsWithdrawn
-
Virginia Commonwealth UniversityNational Institutes of Health (NIH); American Lung AssociationTerminatedDepression | Quality of Life | Sedation | Post-traumatic Stress Disorder | Mechanical Ventilation
-
ETOP IBCSG Partners FoundationAlliance for Clinical Trials in Oncology; Canadian Cancer Trials Group; Breast...Active, not recruitingEarly Breast CancerKorea, Republic of, United States, France, Canada, Spain, Lebanon, Belgium, Switzerland, Israel, Ireland, Japan, Italy, Denmark, Austria, Australia, Greece, Hungary, Netherlands, Norway, Portugal, Serbia, Slovenia
-
Laval UniversityCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie...Not yet recruitingLung Cancer | Surgery | Circulating Tumor CellCanada
-
Canadian Immunodeficiency Research CollaborativeHoffmann-La RocheCompleted